Cellectis S.A. (CLLS)
Cellectis S.A. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Cellectis S.A. (CLLS) is a Biotechnology company based in FR with a market capitalization of $270.1M. Revenue grew 75.8% year-over-year and free cash flow was negative at -$42.5M. This page tracks CLLS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
FR · 216 employees · IPO Mar 24, 2015
Valuation
Valuation & price
$3.70as of May 26, 2026· -30.9% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
3.56
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$270.1M
Market cap
75.8%
Revenue growth (YoY)
86.6%
Gross margin
-$42.5M
Free cash flow (USD)
-$88.8M
Net debt
Net cash position
10.7%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 6-K/A filed Jun 26, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Annual reportJun 26, 2026Filing
Annual Report Filed
- 6-K filingJun 25, 2026Filing
Shareholders Meeting Results
- Annual reportJun 25, 2026Filing
Annual Report Filed
- 6-K filingJun 11, 2026Filing
Clinical Trial Results Presentation
- 6-K filingJun 9, 2026Filing
FDA RMAT Designation
- Annual reportMay 21, 2026Filing
Annual Report Filed
- 6-K filingMay 20, 2026Filing
Annual Shareholders Meeting
- 6-K filingMay 12, 2026Filing
Clinical Data Presentation
- Annual reportMay 11, 2026Filing
Annual Report Filed
- Quarterly reportMay 11, 2026Filing
Quarterly Report Filed
Questions
Frequently asked questions
What is Cellectis S.A.'s market cap?
Cellectis S.A. (CLLS) has a market capitalization of $270.1M.
What is CLLS's P/E ratio?
A meaningful P/E ratio is not available for CLLS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is CLLS's price-to-book (P/B) ratio?
CLLS trades at 3.56 times book value per share.
Are insiders buying CLLS stock?
SEC Form 4 filings show no open-market insider buys at Cellectis S.A. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.